Equashield to Host Symposium Featuring World#s First Drug Compounding Robot with Closed System Transfer Device

Food and Healthcare Press Releases Tuesday April 3, 2018 08:00
PORT WASHINGTON, New York--3 Apr--PRNewswire/InfoQuest
Satellite Symposium at ISOPP 2018 Focusing on Robotics in Cytotoxics to Feature Leading Experts an Augmented Reality Tour of Equashield Pro Hazardous Drug Compounding Robot

Equashield ( equashield.com ), a leading provider of Closed System Transfer Devices (CSTDs) for hazardous drugs, announced today that it will be leading a symposium exploring the use of robotics in cytotoxic drug handling at the International Symposium on Oncology Pharmacy Practice (ISOPP).

The symposium will introduce the Equashield Pro, the first drug compounding robot utilizing Equashield's proprietary CSTD technology. It will also discuss the role that the Equashield Pro will play in increasing pharmacy throughput while simultaneously keeping pharmacists safe.

The symposium will feature presentations from leading industry experts:
  • Yaakov Cass, District Pharmacist Emeritus for the Israeli Ministry of Health, on Robotics in Cytotoxics: The Final Frontier.
  • Dr. Salim Hadad, Director of the Pharmaceutical Services Department at Rambam Medical Center, on What Role Can Equashield Robots Play in Keeping Pharmacists Safe.
Equashield's symposium will also include an augmented reality demonstration of the Equashield Pro robot.

"The Equashield Pro provides the solution to hazardous drug compounding problems encountered by practicing hospital pharmacists on a daily basis," said Marino Kriheli, Co-Founder of Equashield. "By combining leading robotic automation with Equashield's proprietary CSTD technology, the Equashield Pro significantly speeds up the process of compounding hazardous drugs and creates a safer environment for oncology pharmacists around the world."

Utilizing advanced robotic technologies, the Equashield Pro enables quick compounding of a large variety of patient specific chemotherapy doses using a method that shortens the process flow while performing multiple simultaneous tasks. Comparable in size to a standard Biological Safety Cabinet, it is easily integrated into hospital pharmacies, while dose verification software protects against cases of medication dosage and identification errors.

ISOPP 2018 will be held in Shanghai, China, at the Kerry Hotel Pudong - April 11 - 13, 2018. The Equashield symposium will take place from 12:30 - 14:00 on Wednesday, April 11. To set up a meeting with an Equashield representative, please contact info@equashield.com or visit https://www.equashield.com/ .

About Equashield

Equashield is a leading provider of a full range of manual and automated solutions to hospitals for the compounding and administration of hazardous drugs.   Equashield's product suite includes EQUASHIELD II, its flagship Closed System Transfer Device (CSTD), and EQUASHIELD(R) Pro, the first ever closed system drug compounding robot.   Equashield's CSTD is clinically-proven to protect healthcare professionals from hazardous drug exposure.   The globally awarded EQUASHIELD(R) II covers more routes of exposure than alternative systems by preventing contamination of syringe plungers and drug residuals on connector surfaces, as well as exposure to drug vapors. Studies have shown Equashield's CSTD to be faster to deploy and easier to use than competing systems, and the system has passed the proposed 2015 alcohol vapor containment protocol from NIOSH, confirming that it can contain the harshest vapors & emissions. EQUASHIELD is in use by hundreds of hospitals and clinics around the world, and has been both cleared by the FDA under the ONB product code, and substantiated in FDA-cleared labeling as preventing microbial ingress for up to seven days.

For more information: http://www.equashield.com
Follow Equashield on LinkedIn ,   Twitter and Facebook .
Media Contact:
Finn Partners for Equashield
Nicole Grubner
nicole.grubner@finnpartners.com
@nicolegrubner
+1-929-222-8011
Source: Equashield

Latest Press Release

Boehringer Ingelheim has a very successful 2017 financial year

- Sharp increase in net sales to nearly 18.1 billion euros (+15.7 per cent in currency-adjusted terms; +13.9 per cent in euro terms) - Operating income rises significantly to around 3.5 billion euros - Return on net sales of 19.3 per cent - Strengthened...

Merck Receives Patent for CRISPR Technology in China

- Patent in China covers integration of an external DNA sequence into the chromosome of eukaryotic cells - Company to license CRISPR-related patents to interested parties, supports genome-editing research under ethical and legal standards -...

Cell and Gene Therapy Catapult Opens Manufacturing Centre to Accelerate Growth of the Industry in the UK

- Centre will 'bridge the gap' between scientific research and commercialisation of the medicines of the future - Over GBP60 million of Industrial Strategy investment is being used to develop the new centre Today,the Cell and Gene Therapy Catapult's...

Creation of Inceptua Clinical Trial Services Marks New Era for the Company

Inceptua Group (previously Multipharma) today announces that its Clinical Trial Supplies business unit is rebranding to Inceptua Clinical Trial Services. Going forward, all of the group's three business units including Clinical Trial Services, Medicines...

FDI White Paper and Practical Guide Address the Global Burden of Periodontal Disease

FDI World Dental Federation published two resources - a white paper and a practical guide - as part of its Global Periodontal Health Project (GPHP), which aims to bring attention to periodontal health as a priority area for policy worldwide. (Logo:...

Related Topics